AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01501513
Drug: BLI800 approved preparation regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for oral administration prior to colonoscopy
Trial: NCT01501513
Drug: BLI800 investigational preparation regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for oral administration prior to colonoscopy
Trial: NCT03698916
Drug: Celecoxib cream 8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal delivery of 8% Celecoxib
Trial: NCT00890162
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00890162
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01312129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule x 3 doses 12 hours apart
Trial: NCT03720847
Drug: Estradiol Transdermal Patch 0.1 mg/24 hrs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
Trial: NCT03720847
Drug: Inactive Clear Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
Trial: NCT03720847
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
Trial: NCT04257617
Drug: ZL-1201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 \& 2: Escalating dose of ZL-1201, Part 3: three dose levels determined from Part 1 and Part 2.
Trial: NCT03600129
Drug: 30 milliliters of 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 milliliters of 0.9% NaCl used for Quadratus Lumborum Block
Trial: NCT02000947
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).
Trial: NCT01684605
Drug: NESP 60μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated NESP 60μg once intravenously
Trial: NCT01684605
Drug: CKD-11101 60μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated CKD-11101 60μg once intravenously
Trial: NCT02274428
Drug: pneumostem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human umbilical cord blood derived mesenchymal stem cells
Trial: NCT01793935
Drug: Sensoril®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera
Trial: NCT01793935
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.
Trial: NCT06161090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT04215770
Drug: inj co-amoxiclav 50 units/kg/day vs inj Benzyl Penicillin 25000 units/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients of both groups were examined and compared in terms of efficacy of treatment, safety and cost effectiveness
Trial: NCT01726686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03907423
Drug: Rosuvastatin10 mg tablet
RxNorm normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
Trial: NCT03907423
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetic patients treated with Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
Trial: NCT00189514
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, three times a day, volumes equivalent to 120mcg, 240mcg, or 360mcg of pramlintide acetate
Trial: NCT03535870
Drug: Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advair (Fixed dose combination of fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
Trial: NCT02927314
Drug: CF102
RxNorm normalized name: Cannabinoid Receptor Agonist CF102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally q12h
Trial: NCT02927314
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally q12h
Trial: NCT00265291
Drug: fluoxetine or desipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluoxetine 5-40 mg/day desipramine 50-150 mg/day
Trial: NCT03535870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo dry powder administered via the LOMI inhaler device
Trial: NCT00306072
Drug: nutritional herbal extract from Salacia oblonga
RxNorm normalized name: Cydonia oblonga leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02245373
Drug: Antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01540734
Drug: Marketed paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed formulation
Trial: NCT01540734
Drug: Experimental paracetamol formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental formulation
Trial: NCT00081458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo injectable subcutaneously daily into thigh or abdomen
Trial: NCT03523351
Drug: Systemic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
Trial: NCT04505917
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablet of placebo inserted by the study nurse 3 hours before IUD insertion
Trial: NCT03818932
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-Operative Non Opioid Pain Protocol
Trial: NCT03818932
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-Operative Non Opioid Pain Protocol
Trial: NCT03818932
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-Operative Non Opioid Pain Protocol
Trial: NCT01197235
Drug: isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of isotonic saline will be performed 1 hour before angiography
Trial: NCT02475057
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist at the discretion of the treating Urologist/Oncologist for 1 year.
Trial: NCT02400580
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in the treatment arm will receive 1000mg of IV acetaminophen.
Trial: NCT02400580
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in the placebo arm will receive normal saline.
Trial: NCT00726427
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation to achieve maximum tolerated dose
Trial: NCT00726427
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single dose
Trial: NCT02080078
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00827242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following a 4-week placebo lead-in period, subjects received placebo tablet by mouth once daily over a 12-week period.
Trial: NCT02842099
Drug: TA or TAC
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxol, Epirubincin, with or without Cyclophosphamide
Trial: NCT01479530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily; tablet; orally; 16 weeks
Trial: NCT01479530
Drug: Azilect®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg daily; tablet; orally; 16 weeks
Trial: NCT01119222
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo formulations (Capsule, tablet, IV to match the active treatments and to be administered in a double-dummy fashion).
Trial: NCT00380523
Drug: MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04806425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline is given in same volume to normal saline group over the same duration
Trial: NCT04452006
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be provided in HPMC capsules for oral administration.
Trial: NCT01677065
Drug: Immediate-release reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration of reference drug under fasted conditions
Trial: NCT04126668
Drug: CM082 with fed or fasting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The two groups of subjects were given an equal dose of CM082 tablet (200 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of CM082.
Trial: NCT02931110
Drug: CBL0137
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBL0137 administered IV weekly on Days 1 and 8 of repeated 21 day treatment cycles. Number of Cycles: 2 or until progression or unacceptable toxicity develops
Trial: NCT03234751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48 hours of placebo.
Trial: NCT02059460
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03193931
Drug: Methotrexate Injectable Solution
RxNorm normalized name: methotrexate Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
Trial: NCT02117817
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04162275
Drug: Finamine tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: taken Finamine tablets orally
Trial: NCT04162275
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: taken Placebo tablets orally
Trial: NCT00327132
Drug: Omeprazole, Amoxicillin, Clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00604383
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet, orally, daily, up to 42 months
Trial: NCT02298283
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
Trial: NCT03012347
Drug: BAY987517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity. (Formulation: RB# Y73-161)
Trial: NCT03428854
Drug: LNG-IUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levnorgestrel containing IUD
Trial: NCT00520442
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00520442
Drug: acetamin w codeine
RxNorm normalized name: acetaminophen / codeine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02069366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules. Half of the participants in each diagnostic group \[HC = 20; PTSD = 20; TEC = 20\] will receive placebo.
Trial: NCT00649623
Drug: Benicar® Tablets 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg, single dose fasting
Trial: NCT01111292
Drug: Inositol
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03338023
Drug: LY2963016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03338023
Drug: Lantus®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03341429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous injection
Trial: NCT02523638
Drug: Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
RxNorm normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit \[Hct\]\<45%, platelets \[PLTs\]\<400 x 109/L and leukocytes \[WBCs\]\<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
Trial: NCT01068912
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID x 1 day, and Placebo BID x 4 days
Trial: NCT03650608
Drug: Cohort 1: HL217 Ophathalmic Solution QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1 (Once a day)
Trial: NCT03650608
Drug: Cohort 2: HL217 Ophathalmic Solution BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2 (Twice a day)
Trial: NCT03650608
Drug: Cohort 3: HL217 Ophthalmic Solution QID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 3 (Four times a day)
Trial: NCT03650608
Drug: Placebo Ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00356421
Drug: Inhaled Human Insulin (Exubera®)
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preprandial inhaled insulin regimen and administration of insulin glargine QD
Trial: NCT00567112
Drug: 10 mg MK-0941 DFC (fasted)
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state
Trial: NCT00567112
Drug: 10 mg MK-0941 OCT (after meal)
RxNorm normalized name: Urimar Reformulated Oct 2013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal
Trial: NCT00567112
Drug: 10 mg MK-0941 OCT (before meal)
RxNorm normalized name: Urimar Reformulated Oct 2013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast
Trial: NCT00567112
Drug: 10 mg MK-0941 OCT (fasted)
RxNorm normalized name: Urimar Reformulated Oct 2013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state
Trial: NCT00918450
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous dosing until disease progression using one of the following formulations:~25 mg/mL oral solution OR 50 mg/mL oral solution OR 2.0 grams/bottle powder for oral solution of 25 mg/mL when mixed OR 2.0 grams/bottle powder for oral solution of 50 mg/mL when mixed
Trial: NCT01890005
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
Trial: NCT03528577
Drug: Zero-dose
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment A
Trial: NCT03528577
Drug: 90 mcg of PROAIR® HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B
Trial: NCT03528577
Drug: 180 mcg of 90 mcg of PROAIR® HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C
Trial: NCT01789775
Drug: Drug: CD07805/47 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01789775
Drug: CD07805/47 gel Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01940146
Drug: SPARC Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01940146
Drug: SPARC1310 II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPARC1310 II
Trial: NCT01940146
Drug: SPARC1310 III
RxNorm normalized name: CARDIOTOXIN III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPARC1310 III
Trial: NCT04947267
Drug: 2% Mepivacaine with 1:100,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 ml of 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special, Septodont) was administered to Group A patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
Trial: NCT03879109
Drug: Chemotherapy FOLFIRINOX, 6 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * oxaliplatin: 85 mg/m2~* irinotecan: 180 mg/m²~* folinic acid: 400 mg/m2~* 5FU : 400 mg/m2 (bolus)~* 5FU : 2400 mg/m2 (continuous infusion)
Trial: NCT04926584
Drug: induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: induction immuno-chemotherapy or immunotherapy prior to resection or definitive chemoradiotherapy
Trial: NCT03664141
Drug: Cannabis oil
RxNorm normalized name: Cannabis oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with cannabis oil
Trial: NCT03664141
Drug: Placebo/ Regular Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with placebo (Regular Oil)
Trial: NCT04338997
Drug: IZD174
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small molecule inhibitor of NLRP3
Trial: NCT00705822
Drug: Docetaxel + Estramustine + Hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel iv 80 mg + Oral estramustine-pills 140 mg + Oral hydrocortisone-pills 20 mg.~Combination of these 3 drugs every 3 weeks
Trial: NCT01328626
Drug: ABT-199
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A (Cohorts 1-8) and Arm B (Cohort 1-6): Subjects in dose escalation phase will receive 1 dose of ABT-199, followed by 6 days off drug, followed by continuous once daily dosing with ABT-199. Arm B (Cohorts 7+): Subjects in dose escalation phase will receive continuous once daily dosing with ABT-199. Arm A and Arm B: Subjects in expanded safety cohort will receive continuous once daily dosing with ABT-199.
Trial: NCT01724190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04119336
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously on days 1, 8, 15.
Trial: NCT00442689
Drug: ethinyl estradiol 35 mcg and drospirenone 3 mg
RxNorm normalized name: drospirenone
DrugBank: Drospirenone (DB01395)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: one active pill per day for three weeks and then 1 sugar pill per day for one week
Trial: NCT02205814
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intra-articular injection of placebo
Trial: NCT00198120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: same dosing schedule and capsule strength
Trial: NCT01283386
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 mg/m\^2 IV or orally on Days 1-3 of each 28-day cycle for 6 cycles
Trial: NCT01437046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04337073
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before anesthesia induction, M group received intravenous injection of 0.3mg/kg Propofol, while N group received corresponding intravenous normal saline of the same volume. After 1 min, both groups received intravenous injection of dexamethasone sodium phosphate injection of 10mg.
Trial: NCT01531153
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dose.
Trial: NCT01324180
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m\^2/day IV over 15 minutes on day 2
Trial: NCT04515966
Drug: Methylprednisolone Injection [Solu-Medrol]
RxNorm normalized name: methylprednisolone Injection [Solu-Medrol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total 1 ml of injectate consisting of 0.5 ml of depo-Medrol (methylprednisolone acetate 40mg/ml) and 0.5 mL of 1% lidocaine will be injected into the carpal tunnel under ultrasound guidance to deliver it into the target area. After completion of the injection, the distal carpal tunnel is scanned to ensure injectate distribution within the distal aspect of the carpal tunnel.